Compare GDL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDL | NTRB |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 72.6M |
| IPO Year | 2006 | 2019 |
| Metric | GDL | NTRB |
|---|---|---|
| Price | $8.28 | $6.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.6K | ★ 56.2K |
| Earning Date | 01-01-0001 | 12-10-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,651.00 |
| Revenue This Year | N/A | $4,584.65 |
| Revenue Next Year | N/A | $89.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.01 | $2.80 |
| 52 Week High | $8.67 | $9.19 |
| Indicator | GDL | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 46.00 |
| Support Level | $8.25 | $5.68 |
| Resistance Level | $8.50 | $9.19 |
| Average True Range (ATR) | 0.06 | 0.57 |
| MACD | -0.00 | -0.14 |
| Stochastic Oscillator | 38.10 | 22.07 |
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.